- Application under evaluation
- CVMP opinion
- European Commission decision
Overview
The marketing authorisation for Gripovac 3 has been withdrawn at the request of the marketing authorisation holder.
Gripovac 3 : EPAR - Summary for the public
English (EN) (187.44 KB - PDF)
български (BG) (300.12 KB - PDF)
español (ES) (187.56 KB - PDF)
čeština (CS) (288.12 KB - PDF)
dansk (DA) (188.69 KB - PDF)
Deutsch (DE) (190.75 KB - PDF)
eesti keel (ET) (187.74 KB - PDF)
ελληνικά (EL) (298.91 KB - PDF)
français (FR) (189.42 KB - PDF)
italiano (IT) (188.49 KB - PDF)
latviešu valoda (LV) (284.4 KB - PDF)
lietuvių kalba (LT) (424.27 KB - PDF)
magyar (HU) (282.5 KB - PDF)
Malti (MT) (291.38 KB - PDF)
Nederlands (NL) (188.67 KB - PDF)
polski (PL) (292.74 KB - PDF)
português (PT) (188.2 KB - PDF)
română (RO) (268.18 KB - PDF)
slovenčina (SK) (286.3 KB - PDF)
slovenščina (SL) (283.19 KB - PDF)
Suomi (FI) (188.03 KB - PDF)
svenska (SV) (188.05 KB - PDF)
Product information
Gripovac 3 : EPAR - Product Information
English (EN) (481.2 KB - PDF)
български (BG) (759.29 KB - PDF)
español (ES) (484.49 KB - PDF)
čeština (CS) (642.21 KB - PDF)
dansk (DA) (474.81 KB - PDF)
Deutsch (DE) (479.66 KB - PDF)
eesti keel (ET) (471.68 KB - PDF)
ελληνικά (EL) (758.73 KB - PDF)
français (FR) (477.46 KB - PDF)
hrvatski (HR) (529.23 KB - PDF)
íslenska (IS) (400.89 KB - PDF)
italiano (IT) (480.23 KB - PDF)
latviešu valoda (LV) (644.77 KB - PDF)
lietuvių kalba (LT) (543.36 KB - PDF)
magyar (HU) (658.12 KB - PDF)
Malti (MT) (669.53 KB - PDF)
Nederlands (NL) (470.48 KB - PDF)
norsk (NO) (479.16 KB - PDF)
polski (PL) (656.86 KB - PDF)
português (PT) (469.18 KB - PDF)
română (RO) (516.55 KB - PDF)
slovenčina (SK) (885.4 KB - PDF)
slovenščina (SL) (617.84 KB - PDF)
Suomi (FI) (472.89 KB - PDF)
svenska (SV) (470.67 KB - PDF)
Gripovac 3 : EPAR - All Authorised presentations
English (EN) (321.17 KB - PDF)
български (BG) (232.14 KB - PDF)
español (ES) (189.07 KB - PDF)
čeština (CS) (225.62 KB - PDF)
dansk (DA) (192.76 KB - PDF)
Deutsch (DE) (183.98 KB - PDF)
eesti keel (ET) (183.7 KB - PDF)
ελληνικά (EL) (227.2 KB - PDF)
français (FR) (180.4 KB - PDF)
italiano (IT) (185 KB - PDF)
latviešu valoda (LV) (225.13 KB - PDF)
lietuvių kalba (LT) (220.04 KB - PDF)
magyar (HU) (205.62 KB - PDF)
Malti (MT) (230.53 KB - PDF)
Nederlands (NL) (183.36 KB - PDF)
polski (PL) (222.53 KB - PDF)
português (PT) (193.6 KB - PDF)
română (RO) (217.92 KB - PDF)
slovenčina (SK) (222.22 KB - PDF)
slovenščina (SL) (220.02 KB - PDF)
Suomi (FI) (185.05 KB - PDF)
svenska (SV) (194.37 KB - PDF)
Product details
- Name of medicine
- Gripovac 3
- Active substance
- inactivated influenza-A virus
- swine
- International non-proprietary name (INN) or common name
- inactivated influenza-A virus
- swine
- Species
- Pigs
- Anatomical therapeutic chemical veterinary (ATCvet) code
- QI09AA03
Pharmacotherapeutic group
ImmunologicalsTherapeutic indication
Active immunisation of pigs from the age of 56 days onwards including pregnant sows against swine influenza caused by subtypes H1N1, H3N2 and H1N2 to reduce clinical signs and viral lung load after infection.
Onset of immunity: 7 days after primary vaccination.
Duration of immunity: 4 months in pigs vaccinated between the age of 56 and 96 days and 6 months in pigs vaccinated for the first time at 96 days and above.
Active immunisation of pregnant sows after finished primary immunisation by administration of a single dose 14 days prior to farrowing to develop high colostral immunity which provides clinical protection of piglets for at least 33 days after birth.
Authorisation details
- EMA product number
- EMEA/V/C/000157
- Marketing authorisation holder
- Merial S.A.S.
Merial S.A.S.
29 avenue Tony Garnier
69007 Lyon
France - Marketing authorisation issued
- 14/01/2010
- Revision
- 1
Assessment history
Gripovac 3 : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (201.41 KB - PDF)
Gripovac 3 : EPAR - Procedural steps taken before authorisation
English (EN) (160.18 KB - PDF)
Gripovac 3 : EPAR - Scientific Discussion
English (EN) (294.18 KB - PDF)
Committee for medicinal products for veterinary use summary of opinion: Gripovac 3: International Non-proprietary Names (INN): Inactivated vaccine against swine influenza in pigs
English (EN) (211.79 KB - PDF)